产后检测以发现妊娠期糖尿病女性持续性血糖异常
综述指出妊娠期糖尿病女性中约30%存在持续性产后血糖异常,而共识指南推荐的产后4-12周2小时口服葡萄糖耐量试验(OGTT)完成率仅35%。单次采血的血红蛋白A1C检测可能识别更多糖尿病前期患者、规避空腹等患者障碍且实验室变异较小,风险-获益焦点应从以OGTT为金标准的检测性能比较转向促进患者识别的能力。
要点
- 妊娠期糖尿病女性中约30%存在持续性产后血糖异常,低成本干预可预防显性糖尿病。
- 共识指南推荐产后4-12周行2小时OGTT,但仅35%女性完成该检测。
- 单次采血的血红蛋白A1C检测可能识别更多糖尿病前期患者并规避空腹等患者障碍。
核心结论
- 单次采血的血红蛋白A1C检测在识别产后血糖异常方面显示出改善诊断的潜力,风险-获益焦点应从以OGTT为金标准的检测性能比较转向促进患者识别的能力。
- 综述作者就改善血糖异常识别和产后健康的策略提出了建议。
研究设计与样本
- 综述,回顾产后检测相关证据并就改善血糖异常识别和产后健康的策略提出建议。
主要发现
- 妊娠期糖尿病患病率已翻倍,其中约30%存在持续性产后血糖异常(糖尿病前期或糖尿病)。
- 尽管共识指南持续推荐产后4-12周行2小时OGTT,但持续报告显示仅35%的女性完成该检测。
- 医生开具检测的比率可以改善,但产后检测的最大障碍明确与患者相关。
- 提高OGTT检测率的举措仅中等有效,且需要分配工作人员时间,分流了其他临床领域的资源。
- 在妊娠和非妊娠人群中,新兴证据表明与OGTT相比,单次采血的血红蛋白A1C检测可能识别更多糖尿病前期患者、规避空腹等患者障碍,且与OGTT或空腹血糖相比实验室变异更小。
临床怎么用
- 共识指南持续推荐产后4-12周行2小时OGTT。
- 作者建议风险-获益焦点应从以OGTT为金标准的检测性能比较转向报告检测促进患者识别的能力。
- 作者建议采用单次采血检测等替代检测模式以规避患者障碍、改善产后血糖异常的诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rate of gestational diabetes has doubled, and identifying the 30% with persistent postpartum dysglycemia (prediabetes or diabetes mellitus) is important because low-cost interventions have been proven to prevent overt diabetes mellitus, improve health for women, and potentially decrease the risk for birth defects in future pregnancies. Consensus guidelines continue to recommend a 4- to 12-week postpartum 2-hour oral glucose tolerance test (OGTT) despite persistent reports that only 35% of women complete the test. Physician ordering rates can improve, but the largest barriers to postpartum testing are clearly patient-related. Initiatives to improve OGTT testing rates have been only moderately effective and required allocation of staff time, diverting resources from other clinical areas. Alternative testing models using single-draw tests that bypass patient barriers show promise for improving the diagnosis of postpregnancy dysglycemia. Specifically, evidence is emerging in the pregnant and nonpregnant populations that, compared with the OGTT, the single-draw hemoglobin A1C test may identify more patients with prediabetes, bypasses patient barriers to testing such as the need for fasting, and has less laboratory variation compared with the OGTT or fasting plasma glucose. The risk-benefit focus should shift from comparing individual test performance statistics presuming the OGTT to be the "gold standard" to data reporting the ability of a test to facilitate identification of patients. We review the evidence regarding postpregnancy testing and make recommendations for strategies to improve the identification of dysglycemia and postpregnancy health.
引用
- Carson MP, Ananth CV, Gyamfi-Bannerman C, et al. Postpartum Testing to Detect Persistent Dysglycemia in Women With Gestational Diabetes Mellitus. Obstet Gynecol. 2018. PMID: 29889746. doi:10.1097/AOG.0000000000002687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。